Supplemental data for Figure 4.

AUC results of the drug sensitivity screens in conditionally reprogrammed PDAC cells.

Supplemental Figure 4. mRNA abundance in triptolide-treated PDAC 001 cells

Supplemental Figure 3. Testing screen hits in patient-derived xenografts.

Supplemental Figure 2. Rapid derivation of PDAC cells in culture.

ERCC3 interacting proteins.

Supplemental Figure 5. Quantified protein expression in PDAC 001 cells.

Supplemental Figure S1. Rapid derivation of PDAC cells in culture

Table S1. Genetic characterization of patient-derived xenografts using the Illumina Trusight panel capturing frequent mutations in 94 genes and 284 SNPs associated with cancer Table S3. Triptolide-induced effects on the mRNA abundance was determined by Illumina HighSeq RNA sequencing of 001 cells treated with 100 nM triptolide in vitro for 6 hours.